In a recent op-ed published by Canadian SME Magazine, Conscience’s Chief Policy and Partnerships Officer Richard Gold makes the case for why Canadian science-based SMEs should consider open science not just as a philosophy—but as a practical strategy for growth. In an era where funding is uncertain and the costs of pursuing patents are often prohibitive, Gold argues that open science offers a viable and cost-effective alternative, particularly for early-stage companies and those developing treatments for underserved conditions.
The piece features several organizations, including Conscience, that are helping to redefine what sustainable, collaborative innovation can look like in life sciences. It highlights how our programs provide Canadian SMEs with financial and technical support to pursue drug discovery efforts without relying on patents.
